AngioDynamics (NASDAQ:ANGO) Issues Quarterly Earnings Results

AngioDynamics (NASDAQ:ANGO) posted its quarterly earnings results on Thursday. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.04, Zacks reports. AngioDynamics had a negative net margin of 10.01% and a negative return on equity of 4.66%. The business had revenue of $78.42 million during the quarter, compared to analyst estimates of $76.77 million.

Here are the key takeaways from AngioDynamics’ conference call:

• AngioDynamics reported Q3 revenue of $78.4M, up 8.9% YoY with MedTech up 19%, and raised FY26 net sales guidance to $313.5–$315.5M and adjusted EBITDA to $10–$12M (third consecutive upward revision).
• Auryon delivered its nineteenth consecutive quarter of double‑digit growth as increased hospital adoption and product line extensions (radial access, 1.7 mm catheters) drive volume and improved pricing dynamics.
• The combined mechanical thrombectomy portfolio (AlphaVac + AngioVac) grew ~18% YoY, with AlphaVac +47% YoY and +24% sequential, and the company has enrolled first patients in the pivotal APEX‑Return trial targeting approval in Q1 2027.
• NanoKnife revenue rose 21% (capital +24.9%, probes +20%), supported by the Jan 1 implementation of a CPT Category I code and expanded European indications that should boost capital placements and probe utilization.
• Gross margin fell 110 bps to 52.9% due to tariffs, inflation, and a manufacturing transition; tariffs were $1.3M in Q3 and are expected to be $4–$6M for FY26, and a planned $3–$5M inventory build for sterilization shutdowns could make FY26 cash flow slightly negative despite expected strong Q4 cash generation.

AngioDynamics Price Performance

Shares of AngioDynamics stock opened at $10.31 on Friday. AngioDynamics has a 1 year low of $8.36 and a 1 year high of $13.99. The business has a 50 day moving average price of $10.85 and a 200 day moving average price of $11.54. The company has a market capitalization of $424.98 million, a P/E ratio of -13.75 and a beta of 0.43.

Key Headlines Impacting AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Revenue beat and sustained med‑tech growth — AngioDynamics reported roughly $78M in Q3 sales (above estimates) and management highlighted sustained double‑digit growth in its med‑tech businesses, a primary driver cited for upside. AngioDynamics Q3 press release / slide deck
• Positive Sentiment: Company raised full‑year 2026 guidance — management upgraded its outlook following the quarter, which is a near‑term positive catalyst for the stock as investors often reward upward revisions. TipRanks: AngioDynamics raises 2026 guidance
• Neutral Sentiment: Conference call details available — management commentary in the Q3 earnings call and transcripts add color on product performance and margin plans; useful for investors but not a single definitive signal. Seeking Alpha earnings call transcript
• Neutral Sentiment: Elevated trading volume — volume was materially above the average, indicating active re‑pricing and investor interest; this amplifies intraday moves but doesn’t by itself indicate direction. MarketBeat: ANGO trading data
• Negative Sentiment: Mixed/complex earnings metrics — outlets and the call reported differing EPS figures (some showed an EPS miss on certain measures), creating confusion over the underlying profitability picture and raising short‑term risk. InsiderMonkey: earnings call transcript noting EPS miss
• Negative Sentiment: Profitability still mixed — the company reported negative net margin and negative return on equity in the period, signaling that despite top‑line strength, margin improvement and consistent GAAP profitability remain issues for longer‑term valuation. Zacks: Q3 loss and margin data

Wall Street Analyst Weigh In

Several research firms recently weighed in on ANGO. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a report on Wednesday, January 21st. Zacks Research lowered shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a report on Monday, March 30th. Finally, Wall Street Zen cut shares of AngioDynamics from a “buy” rating to a “hold” rating in a research report on Sunday, December 21st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, AngioDynamics has a consensus rating of “Hold” and a consensus price target of $19.33.

Institutional Trading of AngioDynamics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. boosted its stake in shares of AngioDynamics by 9.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock worth $2,434,000 after purchasing an additional 22,658 shares during the last quarter. Jane Street Group LLC boosted its position in AngioDynamics by 267.1% during the first quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier’s stock worth $439,000 after acquiring an additional 34,054 shares during the last quarter. Legal & General Group Plc grew its stake in AngioDynamics by 279.5% in the 2nd quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier’s stock worth $123,000 after acquiring an additional 9,098 shares during the period. Rhumbline Advisers grew its stake in AngioDynamics by 4.3% in the 2nd quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock worth $608,000 after acquiring an additional 2,510 shares during the period. Finally, American Century Companies Inc. raised its holdings in AngioDynamics by 15.8% in the 2nd quarter. American Century Companies Inc. now owns 96,808 shares of the medical instruments supplier’s stock valued at $960,000 after acquiring an additional 13,217 shares during the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.